Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698945 · ClinicalTrials.gov registry record · Phase 4
Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
A Phase 4 study, sponsored by Bp Consulting.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00698945 is a Phase 4 study that has completed, run by Bp Consulting. The registered enrollment target is 40 participants.
The verdict
NCT00698945, a Phase 4 study, has completed, sponsored by Bp Consulting.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I. based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s).
Interventions
- DRUG Alphagan
- DRUG Istalol and Optive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698945
The ClinicalTrials.gov registry entry for NCT00698945 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bp Consulting, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alphagan is the first listed.
NCT00698945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698945 about?
NCT00698945 is a clinical study titled "Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)". To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjuncti...
What is the current status of trial NCT00698945?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2008-06. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00698945?
The interventions under investigation include: Alphagan (DRUG), Istalol and Optive (DRUG).
Who is sponsoring clinical trial NCT00698945?
This trial is sponsored by Bp Consulting, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.